New York State Common Retirement Fund Boosts Stock Position in Enfusion, Inc. (NYSE:ENFN)

New York State Common Retirement Fund increased its stake in Enfusion, Inc. (NYSE:ENFNFree Report) by 17.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,618,803 shares of the company’s stock after acquiring an additional 237,841 shares during the period. New York State Common Retirement Fund owned approximately 1.31% of Enfusion worth $14,521,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Brown Capital Management LLC boosted its stake in shares of Enfusion by 15.0% during the second quarter. Brown Capital Management LLC now owns 9,623,950 shares of the company’s stock worth $107,981,000 after buying an additional 1,254,693 shares during the period. Ararat Capital Management LP boosted its stake in shares of Enfusion by 7.0% during the second quarter. Ararat Capital Management LP now owns 2,435,306 shares of the company’s stock worth $27,324,000 after buying an additional 159,418 shares during the period. BlackRock Inc. boosted its stake in shares of Enfusion by 2.1% during the second quarter. BlackRock Inc. now owns 1,591,827 shares of the company’s stock worth $17,860,000 after buying an additional 32,590 shares during the period. Vanguard Group Inc. boosted its stake in shares of Enfusion by 8.2% during the third quarter. Vanguard Group Inc. now owns 1,524,281 shares of the company’s stock worth $18,809,000 after buying an additional 115,925 shares during the period. Finally, Irenic Capital Management LP acquired a new stake in Enfusion in the second quarter valued at about $13,445,000. 64.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ENFN. JPMorgan Chase & Co. downgraded shares of Enfusion from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $11.00 to $9.00 in a research report on Tuesday, January 30th. UBS Group began coverage on shares of Enfusion in a research report on Tuesday, November 7th. They issued a “neutral” rating and a $9.00 price objective for the company. Finally, Piper Sandler raised their price objective on shares of Enfusion from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $9.80.

Check Out Our Latest Research Report on ENFN

Enfusion Trading Up 1.0 %

NYSE:ENFN opened at $7.91 on Wednesday. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of 98.89, a PEG ratio of 0.99 and a beta of 0.94. The firm’s fifty day simple moving average is $9.21 and its 200 day simple moving average is $9.11. Enfusion, Inc. has a twelve month low of $7.37 and a twelve month high of $12.00.

Enfusion (NYSE:ENFNGet Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Enfusion had a return on equity of 9.13% and a net margin of 3.67%. The firm had revenue of $44.36 million during the quarter, compared to analyst estimates of $43.95 million. On average, analysts predict that Enfusion, Inc. will post 0.09 earnings per share for the current year.

Insider Transactions at Enfusion

In other Enfusion news, CEO Oleg Movchan sold 100,000 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $10.01, for a total value of $1,001,000.00. Following the completion of the transaction, the chief executive officer now owns 1,151,818 shares in the company, valued at approximately $11,529,698.18. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CTO Dan Groman sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $9.97, for a total transaction of $49,850.00. Following the completion of the sale, the chief technology officer now directly owns 133,828 shares of the company’s stock, valued at $1,334,265.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Oleg Movchan sold 100,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $10.01, for a total transaction of $1,001,000.00. Following the sale, the chief executive officer now directly owns 1,151,818 shares of the company’s stock, valued at $11,529,698.18. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,260,926 shares of company stock valued at $12,478,020. Insiders own 39.18% of the company’s stock.

Enfusion Profile

(Free Report)

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.

See Also

Want to see what other hedge funds are holding ENFN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFNFree Report).

Institutional Ownership by Quarter for Enfusion (NYSE:ENFN)

Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.